Hsp104 Variants for Neurodegenerative Disease Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in reversing the proteotoxic misfolding events underlying fatal neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as they lack the ability to efficiently degrade or reactivate misfolded proteins like TDP-43, FUS, and α-synuclein.
Innovation Solution
Development of recombinant Hsp104 proteins with specific missense mutations that enhance the aggregation suppression and degradation of TDP-43, FUS, and α-synuclein, achieved by modifying the middle domain and nucleotide-binding domain 1 of the Hsp104 protein, allowing for effective proteotoxicity reduction and neurodegeneration mitigation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat neurodegenerative diseases, then they provide palliative relief, but they fail to eliminate aggregated misfolded proteins
Solution Approach 1:
The invention modifies the biochemical parameters of Hsp104 by introducing specific missense mutations (e.g., D498V, A503V, D504V, Y507V) in the middle domain and nucleotide-binding domain 1. These parameter changes enhance the protein's disaggregase activity, enabling it to effectively eliminate aggregated misfolded proteins such as TDP-43, FUS, and α-synuclein that cause neurodegenerative diseases.
2Productivity
If Hsp104 protein is used to reduce protein aggregation, then disaggregase activity is enhanced, but the protein requires specific structural modifications to achieve optimal performance
Solution Approach 1:
The invention applies local quality changes by introducing specific missense mutations at defined positions (D498, A503, D504, Y507) in the middle domain and NBD1 of Hsp104. These localized structural modifications selectively enhance disaggregase activity without altering the overall protein structure, allowing the protein to maintain its fundamental function while gaining improved performance against specific aggregated proteins.
3Reliability
If missense mutations are introduced in Hsp104 to enhance aggregation suppression, then biological activity is improved, but the mutation target specificity must be precisely controlled
Solution Approach 1:
The invention uses specific amino acid substitutions (particularly valine mutations at positions 498, 503, 504, and 507) as intermediary changes that mediate the enhancement of aggregation suppression. These controlled intermediary modifications serve as precise levers to tune Hsp104's activity against specific aggregated proteins while maintaining manufacturability and structural integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified Hsp104 variants significantly reduce protein aggregation, restore proper protein localization, and attenuate dopaminergic neurodegeneration in C. elegans models, demonstrating a potent therapeutic potential for neurodegenerative diseases by enhancing disaggregase activity and proteostasis.
Implementation Method 1
Hsp104, a conserved hexameric AAA+ protein from yeast, solubilizes disordered aggregates and amyloid but has no metazoan homolog and only limited activity against human neurodegenerative disease proteins
Implementation Method 2
Here, we reprogram Hsp104 to rescue TDP-43, FUS, and α-synuclein proteotoxicity by mutating single residues in helix 1, 2, or 3 of the middle domain or the small domain of nucleotide-binding domain 1
Implementation Method 3
Provided herein are recombinant Hsp104 proteins of wild type amino acid sequence of SEQ ID NO: 1, comprising a missense mutation in a domain thereof. These include recombinant Hsp104 protein of wild type amino acid sequence of SEQ ID NO: 1, comprising missense mutations that yield a biological activity that reduces aggregation of TDP-43, FUS, or α-synuclein
Data Source
AI summary
Protein misfolding underpins several fatal neurodegenerative disorders. The application is directed to recombinant Hsp104 proteins comprising missense mutations aimed at correcting these events, and methods for expressing and delivering same.